Grandfield & Dodd’s Bristol-Myers Squibb BMY Stock Holding History

Grandfield & Dodd’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$657K	Buy	10,826 +768	+8%	+$44.8K	0.04%	129
2025 Q4	$543K	Sell	10,058 -1,001	-9%	-$48.2K	0.03%	137
2025 Q3	$499K	Sell	11,059 -782	-7%	-$36.5K	0.03%	139
2025 Q2	$548K	Sell	11,841 -515	-4%	-$25.3K	0.03%	135
2025 Q1	$754K	Sell	12,356 -598	-5%	-$34.9K	0.05%	116
2024 Q4	$733K	Sell	12,954 -65	-0.5%	-$3.63K	0.05%	119
2024 Q3	$674K	Sell	13,019 -65	-0.5%	-$3.05K	0.04%	124
2024 Q2	$543K	Sell	13,084 -150	-1%	-$6.71K	0.03%	133
2024 Q1	$718K	Sell	13,234 -906	-6%	-$46.2K	0.05%	120
2023 Q4	$726K	Buy	14,140 +91	+0.6%	+$4.78K	0.05%	118
2023 Q3	$815K	Sell	14,049 -141	-1%	-$8.64K	0.06%	112
2023 Q2	$908K	Sell	14,190 -4,436	-24%	-$297K	0.06%	108
2023 Q1	$1.29M	Sell	18,626 -135	-0.7%	-$9.52K	0.09%	91
2022 Q4	$1.35M	Sell	18,761 -251	-1%	-$18.9K	0.1%	90
2022 Q3	$1.35M	Buy	19,012 +903	+5%	+$65.5K	0.11%	85
2022 Q2	$1.39M	Sell	18,109 -30	-0.2%	-$2.29K	0.11%	86
2022 Q1	$1.32M	Sell	18,139 -753	-4%	-$50.6K	0.09%	91
2021 Q4	$1.18M	Sell	18,892 -296	-2%	-$17.4K	0.08%	94
2021 Q3	$1.14M	Buy	19,188 +174	+0.9%	+$11.5K	0.08%	90
2021 Q2	$1.27M	Buy	19,014 +281	+2%	+$18.3K	0.09%	90
2021 Q1	$1.18M	Buy	18,733 +200	+1%	+$12.4K	0.09%	89
2020 Q4	$1.15M	Buy	18,533 +116	+0.6%	+$7.13K	0.09%	90
2020 Q3	$1.11M	Sell	18,417 -4	-0%	-$241	0.1%	89
2020 Q2	$1.08M	Buy	18,421 +177	+1%	+$10.6K	0.1%	90
2020 Q1	$1.02M	Buy	18,244 +476	+3%	+$29.1K	0.12%	83
2019 Q4	$1.14M	Buy	17,768 +2,544	+17%	+$146K	0.1%	86
2019 Q3	$772K	Sell	15,224 -150	-1%	-$7.05K	0.08%	107
2019 Q2	$697K	Sell	15,374 -277	-2%	-$12.9K	0.07%	112
2019 Q1	$747K	Hold	15,651	–	–	0.08%	105
2018 Q4	$814K	Sell	15,651 -182	-1%	-$9.78K	0.1%	95
2018 Q3	$983K	Hold	15,833	–	–	0.1%	96
2018 Q2	$876K	Sell	15,833 -250	-2%	-$13.5K	0.1%	100
2018 Q1	$1.02M	Sell	16,083 -75	-0.5%	-$4.83K	0.11%	92
2017 Q4	$990K	Sell	16,158 -151	-0.9%	-$9.45K	0.11%	98
2017 Q3	$1.04M	Hold	16,309	–	–	0.12%	93
2017 Q2	$909K	Sell	16,309 -297	-2%	-$16.2K	0.11%	98
2017 Q1	$903K	Buy	16,606 +200	+1%	+$11K	0.11%	96
2016 Q4	$959K	Hold	16,406	–	–	0.12%	93
2016 Q3	$885K	Hold	16,406	–	–	0.12%	94
2016 Q2	$1.21M	Hold	16,406	–	–	0.17%	80
2016 Q1	$1.05M	Hold	16,406	–	–	0.15%	83
2015 Q4	$1.13M	Buy	16,406 +780	+5%	+$51.5K	0.17%	78
2015 Q3	$925K	Buy	15,626 +1,170	+8%	+$74.2K	0.16%	82
2015 Q2	$962K	Buy	14,456 +291	+2%	+$19.2K	0.15%	86
2015 Q1	$914K	Buy	14,165 +250	+2%	+$15.7K	0.14%	85
2014 Q4	$821K	Sell	13,915 -169	-1%	-$9.53K	0.13%	86
2014 Q3	$721K	Sell	14,084 -7,358	-34%	-$368K	0.11%	95
2014 Q2	$1.04M	Sell	21,442 -110	-0.5%	-$5.42K	0.16%	92
2014 Q1	$1.12M	Hold	21,552	–	–	0.18%	88
2013 Q4	$1.15M	Hold	21,552	–	–	0.19%	88
2013 Q3	$997K	Hold	21,552	–	–	0.18%	89
2013 Q2	$963K	Buy	+21,552	New	+$936K	0.18%	88

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grandfield & Dodd's BMY Position: Q1 2026 in Review

Grandfield & Dodd increased its Bristol-Myers Squibb (BMY) stake by 7.6% in Q1 2026, buying an estimated $44.8K and bringing the position to 10,826 shares worth $657K. The position accounts for 0.04% of the portfolio, ranked #129.

Grandfield & Dodd first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.39M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Grandfield & Dodd held 10,826 shares of Bristol-Myers Squibb worth $657K as of Q1 2026.
Grandfield & Dodd bought 768 Bristol-Myers Squibb shares in Q1 2026, an estimated $44.8K.
Bristol-Myers Squibb made up 0.04% of Grandfield & Dodd's portfolio in Q1 2026, its #129 holding.
Grandfield & Dodd first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
Grandfield & Dodd's Bristol-Myers Squibb position peaked at $1.39M in Q2 2022.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.